Phenotypes associated with this allele

• Allele Symbol: Rorc^tm3Litt
• Allele Name: targeted mutation 3, Dan R Littman
• Allele ID: MGI:3818459
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Rorc^tm3Litt/Rorc^tm3Litt Tcrd^tm1.1(cre/ERT2)Zhu/Tcrd^+	B6.Cg-Rorc^tm3Litt Tcrd^tm1.1(cre/ERT2)Zhu	MGI:8449416

Genotype
MGI:8449416

cn1

• Allelic Composition: Rorc^tm3Litt/Rorc^tm3Litt; Tcrd^{tm1.1(cre/ERT2)Zhu}/Tcrd⁺
• Genetic Background: B6.Cg-Rorc^tm3Litt Tcrd^{tm1.1(cre/ERT2)Zhu}

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

decreased tumor growth/size ( J:327132 )

• tamoxifen-treated mice subjected to azoxymethane-dextran sodium sulfate (AOM-DSS) show no differences in colon tumor numbers or burden but show smaller tumors after the second DSS cycle

hematopoietic system

abnormal gamma-delta intraepithelial T cell morphology ( J:327132 )

• tamoxifen-treated mice show decreased Vgamma6+ and Vgamma4+ gamma-delta T cell populations

• however, tamoxifen-treated mice do not show changes in CD8alpha-alpha-expressing gamma-delta T cells

• mice treated with tamoxifen at late stages show reduced frequency of PD-1+ and IL-17-producing tumor-infiltrating gamma-delta T cells

• tamoxifen-treated and AOM-DSS subjected mice show a 55% reduction in tumor-infiltrating Rorgammat⁺ gamma-delta T cells

• however, no difference in Rorgammat expression or IL-17 production among CD4+ T cells

abnormal monocyte morphology ( J:327132 )

• tamoxifen-treated and AOM-DSS subjected mice show a decrease in tumor-infiltrating CD11b+Gr-1^int cells (inflammatory monocytes)

abnormal T cell physiology ( J:327132 )

• tumor-infiltrating CD8alpha-beta⁺ T cells from tamoxifen-treated and AOM-DSS subjected mice show increased IFN-gamma production

immune system

abnormal gamma-delta intraepithelial T cell morphology ( J:327132 )

• tamoxifen-treated mice show decreased Vgamma6+ and Vgamma4+ gamma-delta T cell populations

• however, tamoxifen-treated mice do not show changes in CD8alpha-alpha-expressing gamma-delta T cells

• mice treated with tamoxifen at late stages show reduced frequency of PD-1+ and IL-17-producing tumor-infiltrating gamma-delta T cells

• tamoxifen-treated and AOM-DSS subjected mice show a 55% reduction in tumor-infiltrating Rorgammat⁺ gamma-delta T cells

• however, no difference in Rorgammat expression or IL-17 production among CD4+ T cells

abnormal monocyte morphology ( J:327132 )

• tamoxifen-treated and AOM-DSS subjected mice show a decrease in tumor-infiltrating CD11b+Gr-1^int cells (inflammatory monocytes)

abnormal T cell physiology ( J:327132 )

• tumor-infiltrating CD8alpha-beta⁺ T cells from tamoxifen-treated and AOM-DSS subjected mice show increased IFN-gamma production

increased interferon-gamma secretion ( J:327132 )

• tumor-infiltrating CD8alpha-beta⁺ T cells from tamoxifen-treated and azoxymethane-dextran sodium sulfate (AOM-DSS) subjected mice show increased IFN-gamma production